Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.36 is 63% above its 5-year average of -3.64, near the high end of its 5-year range (-5.86–-1.34).
22.51% above its 12-month average of -1.75.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.36.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.36
EARNINGS PER SHARE (EPS) AVG TTM
-1.75
EARNINGS PER SHARE (EPS) AVG 3Y
-3.23
EARNINGS PER SHARE (EPS) AVG 5Y
-3.64
EARNINGS PER SHARE (EPS) AVG 10Y
-20.51
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+22.51%
CURRENT VS 3Y AVG
+57.96%
CURRENT VS 5Y AVG
+62.64%
CURRENT VS 10Y AVG
+93.37%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Protara Therapeutics, Inc.
Market Cap
$143.60M
Earnings Per Share (EPS)
-1.36
TTM Avg
-1.75
3Y Avg
-3.23
5Y Avg
-3.64
Market Cap
$143.84M
Earnings Per Share (EPS)
-0.61
TTM Avg
-0.35
3Y Avg
-0.32
5Y Avg
-0.30
Market Cap
$143.10M
Earnings Per Share (EPS)
-2.52
TTM Avg
-2.32
3Y Avg
-1.91
5Y Avg
-1.63
Market Cap
$146.27M
Earnings Per Share (EPS)
2.68
TTM Avg
-1.38
3Y Avg
-6.44
5Y Avg
-7.90
Market Cap
$146.28M
Earnings Per Share (EPS)
-0.34
TTM Avg
-0.70
3Y Avg
-0.76
5Y Avg
-0.63
Market Cap
$146.62M
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.85
3Y Avg
-1.46
5Y Avg
-1.46
Market Cap
$139.84M
Earnings Per Share (EPS)
-17.42
TTM Avg
-26.05
3Y Avg
-23.35
5Y Avg
-21.03
Market Cap
$139.47M
Earnings Per Share (EPS)
-1.11
TTM Avg
-1.59
3Y Avg
-2.87
5Y Avg
-3.93
Market Cap
$139.04M
Earnings Per Share (EPS)
-1.04
TTM Avg
-1.66
3Y Avg
-1.77
5Y Avg
-1.60
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | $143.60M | -1.36 | -1.75 | -3.23 | -3.64 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | -0.61 | -0.35 | -0.32 | -0.30 |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -2.52 | -2.32 | -1.91 | -1.63 |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 2.68 | -1.38 | -6.44 | -7.90 |
| Codexis, Inc. (CDXS)vs › | $146.28M | -0.34 | -0.70 | -0.76 | -0.63 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | -1.64 | -1.85 | -1.46 | -1.46 |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | -17.42 | -26.05 | -23.35 | -21.03 |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | -1.11 | -1.59 | -2.87 | -3.93 |
| Immuneering Corporation (IMRX)vs › | $139.04M | -1.04 | -1.66 | -1.77 | -1.60 |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | -0.26 | -0.53 | -0.57 | -0.55 |
Trailing EPS (TTM)
$-1.36
Forward EPS (Est.)
$-1.39
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.34 |
| 2024-12-31 | -2.17 |
| 2023-12-31 | -3.57 |
| 2022-12-31 | -5.86 |
| 2021-12-31 | -4.20 |
| 2020-12-31 | -4.70 |
| 2019-12-31 | -3.63 |
| 2018-12-31 | -9.93 |
| 2017-12-31 | -69.38 |
| 2016-12-31 | -68.90 |
| 2015-12-31 | -51.94 |
| 2014-12-31 | -10.24 |
| 2013-12-31 | -37.43 |
| 2012-12-31 | -37.62 |
